低剂量阿帕替尼治疗晚期恶性肿瘤的临床研究进展

Clinical Research Development of Low Dose Apatinib for Treatment of Malignant Tumor at Advanced Stage

恶性肿瘤的发生、发展与肿瘤本身的血管生成密切相关,其中血管内皮生长因子及其受体信号通路是诱导血管生成最重要的调控途径,也是抗肿瘤药物作用的主要靶点。阿帕替尼是一种新型的抗血管生成剂,是小分子血管内皮生长因子受体2酪氨酸激酶抑制剂。阿帕替尼作为晚期胃癌的推荐用药已经成为共识。由于阿帕替尼治疗恶性肿瘤的疗效与耐受性和其剂量密切相关,高剂量阿帕替尼易引发患者严重的并发症,因此研究低剂量阿帕替尼治疗恶性肿瘤具有重要的临床意义。

The occurrence and development of malignant tumor are closely related to the angiogenesis of tumor. Vascular endothelial growth factor and its receptor signaling pathway are the most important regulatory pathways that induce angiogenesis and are the main targets of antitumor drugs. Apatinib is a new antiangiogenic agent that is a small molecule vascular endothelial growth factor receptor-2,tyrosine kinase inhibitor. It has become the consensus that apatinib is the recommended drug for advanced gastric cancer. The efficacy and tolerability of apatinib in the treatment of malignant tumors are closely related to its dosage,and high-dose apatinib can easily lead to serious complications in patients. Therefore,it is of great clinical significance to study low dose apatinib in the treatment of malignant tumors.